AR046736A1 - Derivados organofosforados de los indazoles y su utilizacion como medicamentos con actividad anticancerosa. - Google Patents

Derivados organofosforados de los indazoles y su utilizacion como medicamentos con actividad anticancerosa.

Info

Publication number
AR046736A1
AR046736A1 ARP040104454A ARP040104454A AR046736A1 AR 046736 A1 AR046736 A1 AR 046736A1 AR P040104454 A ARP040104454 A AR P040104454A AR P040104454 A ARP040104454 A AR P040104454A AR 046736 A1 AR046736 A1 AR 046736A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
nra
cycloalkyl
heteroaryl
Prior art date
Application number
ARP040104454A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR046736A1 publication Critical patent/AR046736A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos químicos, particularmente a derivados organofosforados de los indazoles, a las composiciones que los contienen, y a su utilización como medicamentos para tratar los cánceres. Reivindicación 1: Un producto de la fórmula general (1), en la que: W representa un grupo seleccionado entre un enlace covalente ó O; X representa un enlace covalente, un grupo -C=O-NRa-, NRa-C=O, -(CH2)n-, -CH=CH-, -CsC-, -NRa-, S, O, -SO2-, -SO, -CO, -COO en el cual Ra representa H o un grupo alquilo C1-4 que puede formar eventualmente un ciclo con R1, y en el cual n = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ó 12; R1 representa H (salvo cuando X = -SO2-, -SO-), alquilo, cicloalquilo, arilo, heteroarilo; en el cual R1 puede estar eventualmente sustituido; R y R2, idénticos o diferentes, representan H o un grupo seleccionado entre los radicales alquilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, hidroxi, alcoxi y ariloxi, en los cuales R y R2 están eventualmente sustituidos; Y representa un enlace covalente o un radical seleccionado entre: -C=O-NRa-, -C=O-O-, -C=O-, -(CH2)n-, -SO2-, en el cual Ra se selecciona del grupo constituido por H, alquilo C1-4, y alquilo C1-4 unido a R3 para formar un ciclo; R3 se selecciona del grupo constituido por H (salvo cuando Y es -C=O-O-, o -SO2-), alquilo, cicloalquilo, arilo, y heteroarilo; R3 puede estar eventualmente sustituido; R4, R6 y R7, idénticos o diferentes, se pueden seleccionar independientemente entre: H, halógeno, alquilo C1-4, alcoxi C1-4, ciano, -N(Rb)Rc, -C=O-N(Rb)Rc, -N(Rb)-CO-Rc, en el cual Rb y Rc se seleccionan independientemente entre H, alquilo C1-4, y cicloalquilo C3-6; con la excepción de los restos de grupo de fórmula (2).
ARP040104454A 2003-12-17 2004-11-30 Derivados organofosforados de los indazoles y su utilizacion como medicamentos con actividad anticancerosa. AR046736A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0314778A FR2864084B1 (fr) 2003-12-17 2003-12-17 Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments

Publications (1)

Publication Number Publication Date
AR046736A1 true AR046736A1 (es) 2005-12-21

Family

ID=34630228

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104454A AR046736A1 (es) 2003-12-17 2004-11-30 Derivados organofosforados de los indazoles y su utilizacion como medicamentos con actividad anticancerosa.

Country Status (17)

Country Link
US (1) US7491710B2 (es)
EP (1) EP1732938B1 (es)
JP (1) JP4630285B2 (es)
KR (1) KR20060109942A (es)
CN (1) CN1894264A (es)
AR (1) AR046736A1 (es)
AT (1) ATE430754T1 (es)
AU (1) AU2004299299A1 (es)
BR (1) BRPI0417708A (es)
CA (1) CA2546903A1 (es)
DE (1) DE602004021037D1 (es)
FR (1) FR2864084B1 (es)
IL (1) IL176233A0 (es)
MX (1) MXPA06006832A (es)
TW (1) TW200529828A (es)
UY (1) UY28679A1 (es)
WO (1) WO2005058923A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
EP1763524A1 (en) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
US7550598B2 (en) * 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
DE102004052725B4 (de) * 2004-10-27 2007-07-12 Technische Universität Chemnitz Verfahren zur Herstellung substituierter Phosphane und nach dem Verfahren hergestellte substituierte Phosphane
AU2006209712B2 (en) * 2005-01-27 2011-06-09 Kyowa Hakko Kirin Co., Ltd. IGF-1R inhibitor
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2008001886A1 (fr) 2006-06-30 2008-01-03 Kyowa Hakko Kirin Co., Ltd. Inhibiteur d'aurora
WO2008001885A1 (fr) 2006-06-30 2008-01-03 Kyowa Hakko Kirin Co., Ltd. INHIBITEUR DE KINASE Abl
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
EP2133095A4 (en) 2007-03-05 2012-09-26 Kyowa Hakko Kirin Co Ltd PHARMACEUTICAL COMPOSITION
CN101440092B (zh) * 2008-12-25 2010-11-17 浙江大学 2-吲唑-4-氮杂吲哚-5-氨基衍生物及制备和应用
ES2556350T3 (es) 2009-08-10 2016-01-15 Samumed, Llc Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos
CN102595899A (zh) * 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 作为wnt/b-联蛋白信号传导途径抑制剂的吲唑及其治疗用途
CA2785037C (en) 2009-12-21 2018-01-16 Samumed, Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
KR102010611B1 (ko) 2011-09-14 2019-08-13 사뮤메드, 엘엘씨 인다졸-3-카르복사미드 및 WNT/β-카테닌 신호생성 경로 저해제들로써의 이들 용도
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
PT2770994T (pt) 2012-05-04 2019-11-04 Samumed Llc 1h-pirazolo[3,4-b]piridinas e utilizações terapêuticas destas
JP6355648B2 (ja) 2013-01-08 2018-07-11 サミュメッド リミテッド ライアビリティ カンパニー Ｗｎｔシグナル伝達経路の３−（ベンゾイミダゾール−２−イル）−インダゾール阻害剤およびそれらの治療的使用
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024026A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017079759A1 (en) 2015-11-06 2017-05-11 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
JP6659445B2 (ja) * 2016-04-28 2020-03-04 株式会社トクヤマ 脱ベンジル化方法
SG10201912248RA (en) 2016-06-01 2020-02-27 Samumed Llc Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
MX2019004616A (es) 2016-10-21 2019-11-21 Samumed Llc Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
MA46696A (fr) 2016-11-07 2019-09-11 Samumed Llc Formulations injectables à dose unique prêtes à l'emploi
EP4056558A4 (en) * 2019-11-06 2023-12-27 Jinan University INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND ITS APPLICATIONS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131625A1 (en) * 1992-03-09 1993-09-16 Donald R. James Novel arylindazoles and their use as herbicides
JPH09281630A (ja) * 1996-04-12 1997-10-31 Konica Corp ハロゲン化銀写真感光材料
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Also Published As

Publication number Publication date
WO2005058923A1 (fr) 2005-06-30
EP1732938A1 (fr) 2006-12-20
FR2864084B1 (fr) 2006-02-10
BRPI0417708A (pt) 2007-03-20
JP2007514721A (ja) 2007-06-07
FR2864084A1 (fr) 2005-06-24
US7491710B2 (en) 2009-02-17
CA2546903A1 (fr) 2005-06-30
UY28679A1 (es) 2005-08-31
AU2004299299A1 (en) 2005-06-30
KR20060109942A (ko) 2006-10-23
JP4630285B2 (ja) 2011-02-09
EP1732938B1 (fr) 2009-05-06
IL176233A0 (en) 2006-10-05
MXPA06006832A (es) 2006-09-04
ATE430754T1 (de) 2009-05-15
DE602004021037D1 (de) 2009-06-18
US20050137171A1 (en) 2005-06-23
CN1894264A (zh) 2007-01-10
TW200529828A (en) 2005-09-16

Similar Documents

Publication Publication Date Title
AR046736A1 (es) Derivados organofosforados de los indazoles y su utilizacion como medicamentos con actividad anticancerosa.
AR044909A1 (es) Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia
CO5650164A2 (es) Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
AR036032A1 (es) Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif
AR043199A1 (es) Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes
CO5640090A2 (es) Inhibidores del factor inhibidor de la migracion de los macrofagos y etodo para su identificacion
NO20053994L (no) Fettsyrer med middels kjedelengde, glycerider og analoger som stimulatorer av erytropoese
AR046200A1 (es) Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas
AR043508A1 (es) 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
HUP0402065A2 (hu) Heterobiciklikus szerkezetû hepatitis C vírus polimeráz inhibitorok, eljárás az elõállításukra és ezeket tartalmazó gyógyszerkészítmények
AR036365A1 (es) 1,8-naftiridin-4(1h)-onas alquin-aril sustituidas y composiciones farmaceuticas que las contienen
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
AR040566A1 (es) Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
TNSN05257A1 (en) Beta-carbolines useful for treating inflammatory disease
UY28333A1 (es) Inhibidores de caspasa y sus usos.
YU18999A (sh) Supstituisani tricikli
AR048567A1 (es) Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
ECSP088484A (es) Derivados de quinazolina espirocíclicos como inhibidores de pde7
UY29239A1 (es) Nuevos derivados de piridotienopirimidina
AR024939A1 (es) Compuestos derivados de hidantoina,tiohidantoina, pirimidinonas, tioxopirimidinonas, intermedirios, proceso para su preparacion y su uso de los mismos
AR041864A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure